Pragma Bio adds Dr. Stuart Chaffee to its Board as Independent Director

– USA, CA –  Pragma Bio, an AI-enabled biotechnology company announced the appointment of Dr. Stuart Chaffee (Ph.D.) to its Board as an Independent Director, bringing nearly three decades of experience in the biotechnology and biopharma industry to the board.

The company also appointed Dr. Raquel Izumi (Ph.D.) and Abbas Kazimi as Strategic Advisors.

About Dr. Stuart Chaffee

Dr. Stuart Chaffee has contributed to the inception of four publicly traded biotechnology companies and raised over $900 million in private and public capital. With a recent role as CBO at Affinivax, Inc. exiting for $3.3 billion to GSK, Chaffee’s strategic acumen and leadership are invaluable.

About Dr. Raquel Izumi

Raquel Izumi, PhD, joins Pragma Bio’s advisory team with a wealth of knowledge and experience in clinical development. Izumi has played a pivotal role in advancing breakthrough therapies for cancer patients as the co-founder of Acerta Pharma and Aspire Therapeutics LLC, and with a distinguished tenure at Pharmacyclics LLC. She played an instrumental role in bringing two medicines, CALQUENCE and IMBRUVICA, to market, which exited AstraZeneca and Abbvie, respectively. AstraZeneca bought 45% of Acerta for $4 billion in 2016. After phase 3 milestones were met, AstraZeneca acquired the remaining 45% for nearly $3 billion. Pharmacyclics did a co-development deal with J&J for nearly $1 billion and a few years later, Abbvie bought Pharmacyclics for $21 billion. Abbvie and J&J now co-market IMBRUVICA. These two medicines currently are in the top 15 highest revenue-generating oncology treatments on the market. Izumi’s story has been portrayed in Nathan Vardi’s “For Blood and Money: Billionaires, Biotech and the Quest for a Blockbuster Drug.

About Abbas Kazimi

Abbas Kazimi, M.S., has over 15 years of experience in biotechnology business development and commercialization. Currently serving as CBO at Nimbus Therapeutics, Kazimi has been instrumental in driving key transactions resulting in over $600 million in equity financing and deals worth over a total value of $7 billion, including the landmark $6 billion acquisition by Takeda of the allosteric TYK2 inhibitor program and the associated subsidiary.

About Pragma Bio

Pragma Bio pioneers a tech-driven small molecules discovery pipeline, mapping nature-inspired chemicals within humans for health benefits. Harnessing cutting-edge machine learning and synthetic biology, we drive intelligent discovery and iteratively bio-manufacture novel enzymes with potent biological signals to create new medicines and support biotech discoveries. Our exceptional team, along with our CSO and scientific co-founder, Professor Mohamed Donia from Princeton University, leads our pursuit of innovative solutions. Currently, our exclusive strategy involves mining human multi-omics and Real-World Evidence (RWE) for small molecule discovery to be validated in preclinical models in-house.

For more information: https://www.pragmabio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.